Solbec progresses psoriasis trial
Tuesday, 05 October, 2004
Solbec Pharmaceuticals (ASX:SBP) has completed the first stage of its Phase I clinical trial for a psoriasis treatment based on its lead drug candidate SBP002.
The drug, formulated as a cream, was tested on a number of healthy individuals with no unwanted effects or reactions recorded. The company will now move on to test the treatment at a therapeutic dose, in preparation for larger Phase II trials, expected to commence after the Phase I trial winds up in early 2005.
The clinical trials are being conducted by clinical trials unit CMAX, part of listed Australian company IDT, in Adelaide.
SBP002 is also under investigation by Solbec as a cancer treatment for mesothelioma and melanoma.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
